ASH: Sarclisa 'potential best-in-class therapy' in newly-diagnosed multiple myeloma

Adding Sarclisa (isatuximab) to carfilzomib, lenalidomide and dexamethasone (KRd) caused a statistically-significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation in transplant-eligible patients with newly-diagnosed multiple myeloma (MM).

These results on the Sanofi (Euronext: SAN) drug from the Phase III IsKia trial - conducted by the European Myeloma Network (EMN) - were presented during the oral plenary session at the American Society of Hematology (ASH) Annual Meeting.

"Statistically significant rates of MRD negativity"MRD negativity is defined as the absence of myeloma cells in the bone marrow after treatment, as measured by diagnostic techniques that must have a sensitivity of at least one in 100,000 cells.